Cradle
AI NativeEngineer better proteins, faster.
Engineer better proteins, faster.
Published Sep 27, 2026
The vendor does not publish a comprehensive limitations list in public materials. Some features are labeled as beta in public product descriptions (for example, custom predictor functionality).
Public materials do not specify implementation limits such as sequences per run, plate sizes, API rate limits, or storage/compute contractual caps. The vendor’s marketing language about unlimited data should be validated in contractual terms and SLAs.
SOC 2 is claimed publicly, but other security artifacts (ISO certifications, penetration test reports, detailed encryption/key management information, and data residency options) are not published in the reviewed sources.
Mainstream SaaS review sites (for example, G2 and Capterra) do not contain a meaningful set of verified reviews for cradle.bio at the time of the review. Some listings on review platforms correspond to different products using the same name.
Implication: buyers should expect limited third-party review coverage and plan to rely on reference calls, pilot projects, and technical evaluations.
The vendor publishes customer endorsements and quotes on its website. These vendor-published references indicate usage by named organizations in vendor materials but are marketing references rather than independent reviews.
Searches of public community channels (Reddit, Hacker News) did not surface substantial high-signal discussions about cradle.bio. This may reflect a limited public footprint for an enterprise-focused biotech tool or that discussions occur in private industry forums.
The vendor has published impact metrics (for example, reported ranges of speedups and cost reductions and counts of customers and proteins in development). Public posts do not include standardized methodology for these metrics (for example, baseline definitions, calculation methods, or whether figures represent median vs maximum outcomes). These claims should be validated through reference customers, pilots, and pre-agreed success metrics.
The vendor highlights results from public design challenges and competitions as evidence of performance (for example, an improvement in a binding-affinity benchmark). Such competitions are informative but may not fully reflect constraints present in typical customer programs, including throughput, developability, manufacturability, and regulatory considerations.
Independent coverage has noted that some vendor claims are not fully substantiated in public materials, which underscores the need for buyers to separate illustrative demos and benchmarks from expectations of repeatable, generalizable program acceleration.
Most credible fits appear to be mid-market to enterprise R&D organizations with multiple ongoing protein programs, including biopharma companies and industrial biotech divisions.
Typical organization size examples:
Decision makers:
End users:
Get a comprehensive analysis of Cradle including market position, competitive landscape, adoption trends, and peer benchmarks.
Download full report →Cradle is an enterprise software platform for AI-assisted protein engineering. In practical terms, it supports R&D teams to:
Cradle is marketed under a subscription licensing model rather than a royalty/partnership model; the vendor states that customers retain IP ownership and that customer data is not used to train models for other customers.
Vendor-reported claims requiring scrutiny: Cradle publishes outcome metrics such as reported speedups and cost reductions and an internal satisfaction score. These vendor-published figures are not consistently backed by published methodologies or independent audits and should be validated by buyers.
Target users: protein engineers, computational biologists, ML/bioinformatics teams, and R&D platform teams.
Target organizations include:
Positioning themes (vendor language summarized objectively):